Empagliflozin for Arterial Stiffness
(ERASE-Aging Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must have a stable anti-hypertensive medication regimen for at least 90 days if you are using such medications.
Is empagliflozin generally safe for humans?
How does the drug empagliflozin differ from other treatments for arterial stiffness?
Empagliflozin is unique because it is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that not only helps manage blood sugar levels in type 2 diabetes but also offers cardiovascular and renal protection, which may benefit conditions like arterial stiffness. Its ability to lower blood pressure and promote weight loss further distinguishes it from other treatments.13467
What data supports the effectiveness of the drug empagliflozin for improving arterial stiffness?
Are You a Good Fit for This Trial?
This trial is for men and women aged 60-80 who experience arterial stiffness as they age. Participants must be able to consent, have a specific measure of arterial stiffness (carotid femoral PWV >9.5 m/s), and if taking blood pressure medication, it should be stable for at least 90 days.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 10mg of Empagliflozin or placebo daily for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Empagliflozin
Empagliflozin is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Missouri-Columbia
Lead Sponsor